Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$50.0m

Fortress Biotech Past Earnings Performance

Past criteria checks 0/6

Fortress Biotech's earnings have been declining at an average annual rate of -11.3%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 15.7% per year.

Key information

-11.3%

Earnings growth rate

6.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate15.7%
Return on equityn/a
Net Margin-70.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Revenue & Expenses Breakdown

How Fortress Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:FBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2482-58800
30 Jun 2483-49800
31 Mar 2485-63840
31 Dec 2385-69910
30 Sep 2362-861000
30 Jun 2363-1041080
31 Mar 2364-1001130
31 Dec 2276-951140
30 Sep 2278-971130
30 Jun 2282-931050
31 Mar 2281-74960
31 Dec 2169-65870
30 Sep 2164-38750
30 Jun 2153-33680
31 Mar 2144-43630
31 Dec 2046-47610
30 Sep 2043-576024
30 Jun 2043-545939
31 Mar 2043-545858
31 Dec 1937-405681
30 Sep 1934-455683
30 Jun 1930-515487
31 Mar 1927-535386
31 Dec 1827-735387
30 Sep 18-107-613877
30 Jun 18-65-694573
31 Mar 18-22-724869
31 Dec 1717-654952
30 Sep 17155-745749
30 Jun 17109-604741
31 Mar 1761-553936
31 Dec 1616-553335
30 Sep 164-503230
30 Jun 163-553033
31 Mar 161-492629
31 Dec 151-482230
30 Sep 151-401825
30 Jun 151-271316
31 Mar 151-251215
31 Dec 140-201010
30 Sep 140-261014
30 Jun 140-301017
31 Mar 140-361022

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: FBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:32
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fortress Biotech, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Stephen V. ByrneBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.